002020 Zhejiang Jingxin Pharmaceutical
- 12.71
- +0.10+0.79%
Zhejiang Jingxin Pharmaceutical News
Jingxin Pharmaceutical (002020): Q3 performance is in line with expectations, marketing reform results continue to show
Jingxin Pharmaceutical (002020) Company Brief Review Report: Steady Growth in Performance and Continued Advancement of Commercialization of Innovative Drugs
Jingxin Pharmaceutical (002020): Steady performance growth, commercialization reform results have been achieved
Jingxin Pharmaceutical (002020): Steady growth in performance and the results of marketing reforms are beginning to show
Jingxin Pharmaceutical (002020): Q2 performance exceeded expectations, the finished pharmacy market continued to gain strength
Jingxin Pharmaceutical (002020) Company Brief Review Report: Overall performance remains steady and the release of innovative drugs is imminent
Jingxin Pharmaceutical (002020): Finished drugs are stabilizing and increasing the dosage of new drugs for insomnia can be expected
Pacific released a research report on April 25 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating, and the target price was 18.42 yuan. The main reasons for the rating include: 1) Q1 revenue growth rate was steady, and performance e
Ping An Securities released a research report on April 24 stating that it gave Jingxin Pharmaceutical (002020.SZ) a recommended rating. The main reasons for the rating include: 1) the company's 24Q1 revenue side resumed relatively rapid growth, and the pr
Pacific released a research report on April 9 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating. The main reasons for the rating include: 1) the Q4 revenue growth rate is relatively fast, and the performance is slightly lower than
Deep*Company* Jingxin Pharmaceutical (002020): Steady revenue growth in 2023, sales structure adjustment to promote incremental space expansion
Bank of China Securities released a research report on April 8 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating. The main reasons for the rating include: 1) Achieving net profit of 619 million yuan to mother, a year-on-year decrea
Jingxin Pharmaceutical (002020) 2023 Report Review: Short-term performance is pressured, and the three major businesses are expected to recover steadily
Jingxin Pharmaceutical (002020): Formulation incremental space continues to expand and unleash a new era of innovation
Jingxin Pharmaceutical (002020): Didacinil approved for marketing reforms to expand future incremental space
Jingxin Pharmaceutical (002020): New drug for insomnia approved for marketing, steady growth with multi-wheel drive
Jingxin Pharmaceutical (002020): Innovative drugs are getting better, finished drugs are steadily increasing
Jingxin Pharmaceutical (002020): Capacity Upgrades Release New Momentum, Combining Simulation to Build a Driving Force for Performance Growth
Jingxin Pharmaceutical (002020): Major innovative drugs for insomnia are about to be approved, and the power of central nervous system products continues to strengthen
Jingxin Pharmaceutical (002020): Marketing reform performance is gradually recovering, and the first innovative drug is about to be approved
No Data
